15.23
+5.18%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Biohaven
From its filings with the US Securities and Exchange Commission
Biohaven is based in New Haven, Connecticut and is incorporated in Virgin Islands, British. Its shares trade on NYSE under the ticker BHVN. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported a net loss of $738.8m. At that date it held total assets of $451.4m and shareholders' equity of $52.1m.
Biohaven is a biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. We are advancing our innovative portfolio of therapeutics, leveraging our proven drug development experience and multiple proprietary drug development platforms.
On October 3, 2022, Biohaven Pharmaceutical Holding Company Ltd. (the “Former Parent”) completed the distribution to holders of its common shares of all of our outstanding common shares and the spin-off of Biohaven Ltd. from the Former Parent (the “Separation”). As a result of the Separation, Biohaven became an independent, publicly traded company as of October 3, 2022, and commenced regular way trading under the symbol “BHVN”’ on the New York Stock Exchange on October 4, 2022.
In the fourth quarter of 2025, we initiated strategic portfolio and cost-optimization measures to prioritize three key, late-stage, clinical programs that we believe have the greatest potential for value generation. Our key clinical programs include Kv7 ion channel modulation for epilepsy; Molecular Degrader of Extracellular Proteins (“MoDE”) and Targeted Removal of Aberrant Protein ("TRAP") extracellular protein degradation for immunological diseases; and myostatin-activin pathway targeting agent for neuromuscular and metabolic diseases, including obesity (collectively, the "key programs").
Quoted from its 10-K, filed 2 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 4 May 2017
- Employees
- 274
- Website
- biohavenpharma.com ↗
- Head office
- 215 CHURCH STREET, NEW HAVEN, CT, 06510
- Incorporated in
- D8
- Classification
- Pharmaceutical Preparations
- Filer status
- Large accelerated filer
Leadership
Pay as last reported
- Dr. Vlad CoricChairman of the Board, Chief Executive Officer, since 2015$10.9m
- Mr. Matthew ButenChief Financial Officer$5.3m
- Ms. Kimberly GentileSenior Vice President - Clinical Operations$3.8m
- Dr. Charles ConwayChief Scientific Officer$2.8m
- Mr. William JonesChief Commercial Officer, Migraine and Common Diseases$4.7m
- Dr. Elyse StockChief Medical Officer$3.9m
- Mr. John TiltonChief Commercial Officer, Rare and Orphan Diseases$1.5m
- Mr. Michael HeffernanLead Independent Director$987,799
- Mr. Kishen MehtaDirector$741,908
- Dr. Gregory BaileyIndependent Director$541,826
- Mr. John ChildsIndependent Director$560,013
- Ms. Julia GregoryIndependent Director$560,063
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 58
- Environment
- 29
- Social
- 86
- Governance
- 61
- Women in the workforce
- 58%
- Carbon reduction policy
- No
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Biohaven's glutamate platform includes three clinical-stage product candidates targeting neurological diseases.
- BHV-0223 is in development for ALS, a neurodegenerative disease affecting nerve cells.
- The company focuses on rare neurological disorders with unmet medical needs.
Weaknesses
- Biohaven has 274 employees, which is lower than the industry average for biotech firms.
- The company's IPO was in 2017, indicating a relatively young market presence.
- Limited product pipeline beyond neurological indications in development.
Opportunities
- Expanding into Rett syndrome and neuropathic pain with BHV-5000 for neurological and psychiatric illnesses.
- Growing market for treatments targeting obsessive-compulsive disorder (OCD) and Alzheimer's disease.
- Potential for partnerships in the Health Care sector for rare neurological disorders.
Threats
- Competition in the ALS treatment market from established biotech companies.
- Regulatory challenges for clinical-stage biopharmaceuticals in the Health Care sector.
- High costs associated with developing treatments for rare neurological disorders.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.